Tofacitinib for managing granuloma formation after dermal filler injection: three case reports and literature review
CONCLUSION: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.PMID:38632962 | DOI:10.1080/09546634.2024.2338281 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Jieyi Wang Zhuoxuan Chen Lin Wu Yan Liao Bo Yu Source Type: research

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research

Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research

Tofacitinib for managing granuloma formation after dermal filler injection: three case reports and literature review
CONCLUSION: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.PMID:38632962 | DOI:10.1080/09546634.2024.2338281 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Jieyi Wang Zhuoxuan Chen Lin Wu Yan Liao Bo Yu Source Type: research

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research

Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research

Methodological quality of systematic reviews on atopic dermatitis treatments: a cross-sectional study
CONCLUSIONS: Methodological quality of SRs on AD treatments is unsatisfactory. Future reviewers should improve the above critical methodological aspects. Resources should be devolved into upscaling evidence synthesis infrastructure and improving critical appraisal skills of evidence users.PMID:38626923 | DOI:10.1080/09546634.2024.2343072 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 16, 2024 Category: Dermatology Authors: Leonard Ho Yolenda Man Kei Cheung Cyrus Chung Ching Choi Irene Xinyin Wu Chen Mao Vincent Chi Ho Chung Source Type: research

Artificial intelligence-based prescription of personalized scalp cosmetics improved the scalp condition: efficacy results from 100 participants
Conclusions: SPI-AI accurately assessed the scalp condition. AI-based prescription of tailored scalp cosmetics could significantly improve scalp health.PMID:38616301 | DOI:10.1080/09546634.2024.2337908 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 14, 2024 Category: Dermatology Authors: Bo Ri Kim Min Jae Kim Jieun Koo Hwa-Jung Choi Kyung Ho Paik Soon Hyo Kwon Hye-Ryung Choi Chang Hun Huh Jung Won Shin Dong-Sun Park Jung-Im Na Source Type: research

Topical clindamycin for acne vulgaris: analysis of gastrointestinal events
Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data a...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Natalia M Pelet Del Toro Andrew Strunk Jashin J Wu Linda Stein Gold James Q Del Rosso Robert T Brodell George Han Source Type: research

A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy
J Dermatolog Treat. 2024 Dec;35(1):2338280. doi: 10.1080/09546634.2024.2338280. Epub 2024 Apr 3.ABSTRACTFor individuals with atopic dermatitis (AD), interpreting scientific papers that present clinical outcomes including the Eczema Area and Severity Index (EASI) and Investigators Global Assessment may be difficult. When compared to tabulated data and graphs, images from before and after treatment are often far more meaningful to these patients that ultimately will be candidates for the treatment. This systematic review focused on determining the frequency of clinical image sharing in AD research.Conducted in accordance wit...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Sam Polesie Mikael Alsterholm Source Type: research